📅 2026 Update: New Treatments and Guidelines for Mesothelioma

Since the original article was written, there have been significant updates in the treatment landscape for mesothelioma. The U.S. Food and Drug Administration (FDA) has approved new therapies that may change how patients manage this disease.

The earlier article continues further down the page, providing important background information.

🩺 FDA Approvals for New Treatments

In September 2024, the FDA approved Keytruda® (pembrolizumab) as a first-line treatment for unresectable advanced or metastatic pleural mesothelioma. This drug works best when combined with pemetrexed and platinum chemotherapy. The KEYNOTE-483 clinical trial showed that this combination led to a median overall survival of 17.3 months, compared to 16.1 months for those receiving chemotherapy alone.

💊 Combination Therapy Gains FDA Approval

Additionally, the FDA approved the combination of Opdivo® (nivolumab) and Yervoy® (ipilimumab) in 2024. This treatment is for patients with inoperable malignant pleural mesothelioma. The CheckMate 743 trial noted a median overall survival of 18.1 months for patients using this combination, compared to 14.1 months for those on chemotherapy alone.

🔍 New Guidelines on Surgical Treatment

The National Comprehensive Cancer Network (NCCN) updated its guidelines for 2026 regarding surgical options for pleural mesothelioma. They now recommend pleurectomy/decortication (P/D) over extrapleural pneumonectomy (EPP). The guidelines state that EPP should only be considered in rare cases, and surgery is no longer recommended for stages 2 through 4 of any cell type.

💰 Current Treatment Costs

As of October 2026, the average wholesale price for Keytruda® is approximately $10,000 per 100 mg vial. For the combination of Opdivo® and Yervoy®, the AWP for Opdivo® is about $7,000 per 100 mg vial, while Yervoy® costs around $1,200 per 50 mg vial. The total treatment cost will vary based on dosage, frequency, and patient insurance.

📌 Key Points Summary

  • 🩺 Keytruda® approved for advanced pleural mesothelioma.
  • 💊 Opdivo® and Yervoy® combination shows improved survival.
  • 🔍 NCCN recommends P/D over EPP for surgery.
  • 💰 Current costs for new treatments are significant.
  • 📅 Ongoing clinical trials may provide additional options.

💡 Tips for Mesothelioma Patients

Review all details of your situation with your attorney.

🏥 Understand Your Treatment Options

Stay informed about the latest treatments for mesothelioma. New medications like Keytruda® and the Opdivo® and Yervoy® combination may offer better survival rates. Discuss these options with your healthcare provider.

📅 Explore Clinical Trials

Consider enrolling in clinical trials. These trials often provide access to cutting-edge treatments that are not widely available yet. Consult your healthcare provider for specific enrollment details and eligibility.

💰 Check Financial Assistance

Look into financial assistance programs for funding your treatment. Nonprofits and government organizations may provide resources to help cover the costs of medications and therapies.

🩺 Follow Up Regularly

Keep up with regular follow-up appointments. Monitoring your health closely can help adjust treatment plans as needed. Early intervention can lead to better outcomes.

🤝 Seek Support

Don’t hesitate to reach out for support. Organizations like the Mesothelioma Applied Research Foundation can offer resources and guidance. Connecting with others facing similar challenges can provide emotional relief.

🏆 Free Options Ranked by User Reviews (2026)

No paid national services qualified based on user reviews for this topic, so we focus on free government and nonprofit resources.

🥇 1. Mesothelioma Applied Research Foundation

This nonprofit provides resources, support, and information specific to mesothelioma treatments. They help patients navigate clinical trials and understand treatment options. Their focus is on improving patient outcomes through research and education.

🥈 2. National Cancer Institute (NCI)

The NCI offers comprehensive information on mesothelioma, including treatment options and clinical trials. They provide detailed guides and resources, helping patients and families understand their choices. The NCI also connects patients to additional support services.

🔎 What to Check Before Paying for Help

  • 💬 Confirm the organization’s reputation and reviews.
  • 📜 Verify their accreditation and mission.
  • 🔍 Understand any associated fees or hidden costs.
  • 📅 Ensure they offer updated and accurate information.
  • 🤝 Look for resources that provide ongoing support.

❓ Frequently Asked Questions

❓ What is pleural mesothelioma?

Pleural mesothelioma is a type of cancer that affects the lining of the lungs. It is often caused by exposure to asbestos. Symptoms may include chest pain, shortness of breath, and persistent cough.

🤔 How is mesothelioma diagnosed?

Diagnosis typically involves imaging tests like X-rays or CT scans, followed by a biopsy to confirm the presence of cancer cells. Early diagnosis can improve treatment outcomes.

🏥 What are the common symptoms of mesothelioma?

Common symptoms include persistent cough, chest pain, weight loss, and difficulty breathing. These symptoms can vary based on the stage of the disease and the individual patient.

💊 What treatments are available for mesothelioma?

Treatment options include surgery, chemotherapy, and radiation therapy. New immunotherapy treatments, like Keytruda® and the Opdivo® and Yervoy® combination, are also becoming available.

📅 How often should I follow up with my doctor?

Regular follow-up appointments are essential for monitoring the disease and adjusting treatment plans. Patients should discuss a follow-up schedule with their healthcare providers.

🏆 Are there clinical trials for mesothelioma?

Yes, there are ongoing clinical trials that test new treatments for mesothelioma. Patients are encouraged to discuss potential participation with their healthcare providers.

⚖️ Recent Cases Related to Mesothelioma

Recent court rulings have addressed issues surrounding asbestos exposure and mesothelioma claims. These rulings can impact how individuals seek justice and compensation for their conditions.

Readers can browse more rulings on the news page to stay updated on recent decisions.

End of October 2026 Update






 



What is Paclitaxel? 



 

Paclitaxel


 



Paclitaxel is a mitotic inhibitor applied to cancer patients to combat the disease. Paclitaxel was discovered in a U.S. National cancer Institute program at the Research Triangle Organization. The drug is derived from the bark of the Pacific yew tree. When it was initially developed commercial—by Bristol-Myers Squibb—the drug was given the generic name TAXOL. In this formation, Paclitaxel is dissolved in etahnol and Cremophor EL. A revised formulation, where Paclitaxel is adhered with albumin is sold under the generic name Abraxane. 



 



 



Currently, Paclitaxel is used to treat patients with ovarian, lung, breast neck and head cancer. Paclitaxel is also used to prevent restenosis. The drug stabilizes microtubules and as a result, interferes with the natural breakdown of microtubules during cellular division. When combined with docetaxel, Paclitaxel forms the drug category of the taxanes. 



 



 



While offering significant improvement in patient care, Paclitaxel is regarded as a relatively controversial chemotherapy drug. Original concern over the drug stems from the environmental impact of its source—Paclitaxel is no longer used from the Pacific yew tree. Moreover, the assignment of rights and the name itself were the subject of Congressional hearings and public debate. 



 



 



As a taxane—compounds that are found in natural sources—Paclitaxel attempts to prevent the traditional progression of cell division, making cells unable to divide into sibling structures. Research suggests that Paclitaxel induces a programmed cell termination or apoptosis. 



 



 



Paclitaxel was approved by the United States Food and Drug Administration during the summer of 1992 for the treatment of lung, ovarian and breast cancer. Paclitaxel is also used to combat head and neck cancer, as well as small cell lung cancers and bladder cancers. Paclitaxel is also under investigation for mesothelioma treatment. To fight mesothelioma cancer, Paclitaxel is combined with cisplatin—the platinum-containing chemo drug. Paclitaxel is prescribed worldwide and is applied through an IV once every 2 or 3 weeks. 



 



 



Paclitaxel Side Effects:



 



 



Common side effects associated with Paclitaxel include: loss of appetite, change in taste, vomiting, nausea, brittle or thinning hair, pain in the arms, legs and joints, changes in the colors of finger and toe nails and tingling in the patient’s hands and toes. More severe side effects attached to Paclitaxel include: unusual bleeding and bruising, dizziness, difficulty swallowing, severe exhaustion, skin rash, female infertility, facial flushing, explosive diarrhea, persistent cough and extreme fatigue. The majority of these side effects are related with the excipient used. Allergies to drugs such as teniposide, polyoxyethylated and cyclosporine indicate an increased risk of adverse side effects of Paclitaxel. Before Paclitaxel is administered, the patient will receive a small dose of Dexamethasone to mitigate some of these adverse side effects. Moreover, an application of Leuprolide may prevent—according to mice studies—ovarian damage. 



 



 



How does Paclitaxel Work?



 



 



Paclitaxel-treated cells are targeted for defects in their spindle assembly, chromosome segregation and cellular division. Dissimilar to other tubulin-targeting drugs that inhibit microtubule assembly, Paclitaxel stabilizes the microtubule polymer and shields to from detachment or damage. As a result, chromosomes are not able to achieve a metaphase spindle configuration. This mechanism blocks the progression of mitosis and a prolonged activation of the mitotic checkpoint triggers instability or a reversion to the G-phase of the cycle without incurring cellular division. 



 



 



Paclitaxel’s ability to inhibit spindle function is typically attributed to its suppression of microtubule dynamics; however, recent studies have shown that suppression of dynamics takes place at concentrations that are ruled significantly lower than those required to block mitosis from occurring. At higher therapeutic concentrations, Paclitaxel will appear to suppress microtubule detachment—this process is typically activated during mitosis. The adhering site for v is identified as being on the beta-tubulin sub unit.  



 



 



With regards to clinical use, Paclitaxel is approved in the United Kingdom for breast, lung and ovarian cancers. The bulk of oncologists recommend that Paclitaxel should be used as a second-line treatment for ovarian cancers. 



 



 



Aside from its clinical use, Paclitaxel  is used in a number of biomedical and biological research experiments as a microtubule stabilizer. In tests involving microtubules, including motility assays, scientists typically rely on Paclitaxel to maintain a microtubule integrity only in the absence of several nucleating factors and other stabilizing elements located in the cell. For instance, the drug is used in vitro tests of drugs that attempt to alter the behavior of motor proteins or for the clinical examinations of mutated motor proteins. In rare cases, Paclitaxel is used for in vivo examinations; the drug may be fed to test organisms (mice or fruit flies) or injected into cells to inhibit microtubule fragmentation or to increase the amount of microtubules in the cell. 



 



 



Paclitaxel History of Clinical Trials:



 



 



Paclitaxel Phase I clinical trials began in the Spring of 1984; the decision to advance to stage clinical trials was affirmed later in the year. Subsequent and larger clinical trials to test Paclitaxel required more bark. Although 12,000 pounds of bark was taken from the environment, it was recognized, in 1986, that the demand for Paclitaxel might be substantial and that an excess of 60,000 pounds of bark was required as a minimum. This large amount brought several environmental concerns to the forefront, specifically regarding the impact on the yew population. 



 



 



The first public reports from phase II trials were released in May of 1998 and showed a tremendous effect in melanoma patients and a fantastic response at a rate of 30% for patients suffering from ovarian cancer. At this stage in clinical trials, several oncologists and leaders in the medicine community, calculated the synthesis of enough Paclitaxel to treat melanoma and ovarian cancer cases in the United states would require the destruction of 360,000 trees per year. For the first time in the drug’s existence, serious consideration was given concerning the problem of supply. 



 



 



In response to the supply problem, the National Cancer Institute sough association with a pharmaceutical company to secure funding for the further collection of raw materials, the funding needed to pay for a large proportion of clinical trials and the ability to isolate Taxol. Only 4 companies responded to the NCI’s pleae, including the American giant Bristol-Myers Squibb. In 1990, Bristol-Meyers applied to trademark the name taxol as TAXOL. During this time, Paclitaxel replaced taxol as the generic name of the compound.